Size and characteristics of private TB drug market.

*% of all incident cases that can be treated by first line drugs in private market (average across 4 first line drugs, assuming daily 6–8 month regimen). Data for this and other columns, unless noted, are for Q4 2008–Q3 2009. ∧Denotes countries in which > = 90% of first line TB drugs in the private sector are loose. #Assuming daily dosing for 18 month regimen, and no use for drug-sensitive TB. &Assuming daily dosing for 6 month regimen, and no diagnosis of drug-resistant TB.